Last updated: August 1, 2026
PHISOHEX, a 3% hexachlorophene topical cleanser, has no identifiable active clinical-development program, meaningful patent exclusivity, or current growth market. Its commercial relevance is historical and regulatory rather than pipeline-driven. Hexachlorophene’s use declined sharply after reports of neonatal and pediatric neurotoxicity, and modern antiseptic markets have shifted toward chlorhexidine, povidone-iodine, alcohol-based products, and other formulations with broader use profiles.[1][2]
What is PHISOHEX and what drug does it contain?
PHISOHEX is a topical skin cleanser containing hexachlorophene at a concentration of approximately 3%. Hexachlorophene is a bisphenolic antiseptic with activity against several gram-positive organisms, including staphylococci. Its activity against gram-negative organisms, fungi, and viruses is limited compared with several modern alternatives.[1]
The product was historically used for surgical handwashing, preoperative skin preparation, and cleansing of patients at risk of bacterial infection. Its label restricted use because repeated or extensive exposure could increase systemic absorption and neurological toxicity, particularly in premature infants, newborns, and patients with damaged skin.[1]
PHISOHEX drug profile
| Attribute |
PHISOHEX |
| Active ingredient |
Hexachlorophene |
| Historical concentration |
3% topical formulation |
| Dosage form |
Topical emulsion or cleanser |
| Therapeutic category |
Topical antiseptic and antibacterial cleanser |
| Primary historical uses |
Surgical scrubbing, patient cleansing, infection-control applications |
| Administration |
Topical |
| FDA pathway |
Legacy prescription drug product |
| Current clinical development |
No active development program identified |
| Biosimilar relevance |
None |
| Generic-drug relevance |
Limited and commercially weak |
What is the current FDA status of PHISOHEX?
PHISOHEX is not a current growth product in the U.S. pharmaceutical market. The FDA has issued substantial safety restrictions for hexachlorophene because of neurotoxicity associated with repeated or extensive use. The product is not appropriate for routine infant bathing or unrestricted whole-body cleansing.[1][2]
The FDA’s historical actions followed reports of toxic effects in infants, including cases associated with absorption through the skin. The agency subsequently limited labeling and removed hexachlorophene products from general over-the-counter availability. Hexachlorophene use became restricted to prescription or institutional settings with specific safety controls.[1]
The U.S. regulatory position can be summarized as follows:
- Hexachlorophene is not a routine consumer antiseptic.
- It is not a preferred general-purpose surgical or hospital cleanser.
- Use in newborns, premature infants, and patients with burns or extensive skin damage is highly restricted or contraindicated.
- Product availability depends on the status of individual manufacturers and distributors.
- The drug has no modern FDA exclusivity period supporting commercial protection.
What is the Orange Book status of PHISOHEX?
PHISOHEX does not have a commercially relevant Orange Book patent position. Any historical patents associated with the active ingredient, formulation, or original product development would have expired decades ago. Hexachlorophene was introduced long before the modern Hatch-Waxman exclusivity period and does not have a current new chemical entity, orphan-drug, or pediatric exclusivity position.
No current patent estate is known to provide meaningful protection against competing topical antiseptic products. A manufacturer seeking to commercialize a hexachlorophene product would face regulatory, safety, manufacturing, and market-access barriers rather than patent barriers.
Are there active clinical trials for PHISOHEX?
No active interventional clinical-trial program for PHISOHEX or hexachlorophene is identifiable in the modern clinical-development landscape. The published evidence base consists primarily of historical safety studies, older antiseptic comparisons, case reports, and regulatory reviews rather than contemporary randomized trials designed to support a new indication or commercial relaunch.[1][3]
Clinical-trial status
| Clinical-development category |
Current assessment |
| Phase 1 studies |
None identified |
| Phase 2 studies |
None identified |
| Phase 3 studies |
None identified |
| Registration-enabling program |
None identified |
| Pediatric development |
Not commercially viable because of safety restrictions |
| New formulation trials |
None identified |
| Combination-product trials |
None identified |
| Biosimilar or interchangeable product trials |
Not applicable |
The absence of trials is consistent with the product’s commercial position. PHISOHEX is an old topical antiseptic with a constrained label, weak differentiation, and a safety profile that limits use in the populations most likely to require broad antiseptic cleansing.
When did PHISOHEX lose commercial momentum?
PHISOHEX lost commercial momentum after the FDA’s actions against routine hexachlorophene use in the 1970s. The central concern was neurological toxicity following absorption through infant skin, especially with repeated bathing or application to damaged skin.[1]
The commercial decline followed several developments:
| Period |
Event or market effect |
| Before the 1970s |
Hexachlorophene used in hospitals and consumer hygiene products |
| Early 1970s |
Reports of neonatal neurotoxicity increased regulatory concern |
| 1970s |
FDA restricted OTC availability and narrowed permitted use |
| 1980s-1990s |
Hospitals increasingly adopted alternative antiseptics |
| 2000s onward |
Chlorhexidine, povidone-iodine, and alcohol-based products gained share |
| Current market |
Hexachlorophene remains a legacy, niche, or discontinued product category |
The loss of market position was driven more by safety and clinical-practice changes than by patent expiry. Patent expiration removed exclusivity, but the larger commercial problem was that competing products offered broader institutional utility and fewer restrictions.
What alternatives compete with PHISOHEX?
PHISOHEX competes in the broad antiseptic and skin-disinfection category, not in a viable branded-drug segment. The leading alternatives are chlorhexidine gluconate, povidone-iodine, isopropyl alcohol, ethyl alcohol, benzalkonium chloride, and combination surgical-preparation products.
PHISOHEX compared with major antiseptic alternatives
| Product category |
Main advantage |
Main limitation relative to PHISOHEX |
| Chlorhexidine gluconate |
Broad, persistent antimicrobial activity; strong hospital adoption |
Ototoxicity and ocular risks in certain applications |
| Povidone-iodine |
Broad-spectrum activity and extensive clinical familiarity |
Less persistent activity; iodine-related precautions |
| Alcohol-based preparations |
Rapid action and low residue |
Limited persistence; flammability |
| Benzalkonium chloride |
Consumer and topical applications |
Variable activity and resistance concerns |
| Hexachlorophene |
Persistent activity against selected gram-positive bacteria |
Neurotoxicity concerns, narrow use, weak modern differentiation |
Chlorhexidine-based surgical and patient-cleansing products represent the most important commercial substitute. 3M’s CHG products, BD’s antiseptic products, and other hospital suppliers compete through clinical protocols, procurement contracts, packaging, and infection-control evidence rather than long-term patent exclusivity alone.
What patents protect PHISOHEX?
No unexpired patent estate is known to protect the historical PHISOHEX product or its hexachlorophene active ingredient. The relevant intellectual-property position is effectively expired.
Potential historical protection may have covered:
- Hexachlorophene compositions;
- Emulsion or cleanser formulations;
- Packaging and dispensing systems;
- Manufacturing methods;
- Antiseptic use claims.
Those categories do not create a current barrier to entry. Any present-day market entrant would need to establish regulatory compliance, product quality, toxicology controls, and commercial distribution. A reformulated hexachlorophene product could theoretically generate new formulation patents, but such patents would not restore exclusivity over hexachlorophene itself and would face a difficult regulatory and reimbursement environment.
How strong is the PHISOHEX patent estate?
The current patent estate is commercially weak for four reasons:
- The active ingredient is old and off-patent.
- Historical product patents would have expired.
- Generic or private-label antiseptic products can compete without infringing legacy rights.
- New patents would likely protect narrow formulations rather than the underlying drug.
Patent litigation risk is therefore low. Product-liability, regulatory, and market-acceptance risks are materially higher.
What generic entry risks exist for PHISOHEX?
Generic entry risk is high in the legal sense because no meaningful patent barrier remains. Commercial generic entry risk is lower because demand is limited and the product has weak clinical positioning.
A prospective manufacturer would need to address:
- FDA approval or regulatory authorization for the specific product;
- Current good manufacturing practice compliance;
- Stability and preservative data;
- Dermal absorption and toxicology;
- Labeling restrictions;
- Pediatric contraindications;
- Distribution through hospitals or specialty channels;
- Product-liability exposure;
- Competition from established antiseptic brands.
The likely generic-launch model would be a low-volume institutional product, not a large retail launch. The product would need a defined clinical niche, such as a narrowly specified gram-positive skin-cleansing application, to justify commercial development.
Does PHISOHEX have biosimilar risk?
No. PHISOHEX is a small-molecule topical antiseptic, not a biologic. Biosimilar regulations do not apply. Any competition would arise through generic-drug, abbreviated-approval, private-label, or alternative-antiseptic pathways.
What is the PHISOHEX market size and revenue outlook?
PHISOHEX does not have a transparent, separately reported global market with reliable public revenue estimates. Historical branded revenue is not a useful indicator of current opportunity because the product category has contracted and many sales channels have disappeared or become difficult to verify.
Commercial projection
| Forecast period |
Expected market direction |
Primary rationale |
| 2025-2026 |
Flat to declining |
Limited availability, weak demand, alternative antiseptics |
| 2027-2029 |
Low single-digit decline or niche stabilization |
Possible institutional use but no broad adoption |
| 2030 onward |
Minimal and highly fragmented |
Legacy product status and limited clinical differentiation |
A base-case forecast is for a negligible or declining PHISOHEX market rather than material pharmaceutical growth. A relaunch would require new clinical evidence, a tightly defined indication, and a safety-management strategy. Even then, the addressable market would likely remain small compared with chlorhexidine and povidone-iodine products.
Which companies could challenge or replace PHISOHEX?
The principal competitive threat comes from antiseptic manufacturers rather than generic-drug specialists. Relevant competitors include suppliers of chlorhexidine, povidone-iodine, alcohol-based surgical preparations, and hospital skin-cleansing systems.
Competitive pressure is strongest from products that have:
- Established hospital procurement contracts;
- Current infection-control guideline support;
- Broad distribution;
- Multiple package sizes;
- Surgical and preoperative indications;
- Established safety-monitoring practices;
- Reimbursement or institutional purchasing familiarity.
No major company is known to be pursuing a high-value PHISOHEX litigation or licensing strategy. Licensing interest would be limited unless a manufacturer developed a substantially improved delivery system with a clinically compelling safety advantage.
What manufacturing and intellectual-property barriers affect PHISOHEX?
Manufacturing barriers are more important than patent barriers. Hexachlorophene products require control of concentration, emulsion uniformity, preservative performance, microbiological quality, packaging compatibility, and dermal exposure.
A modern manufacturer would also face:
- Validation of batch consistency;
- Stability testing over the proposed shelf life;
- Container-closure qualification;
- Assessment of systemic absorption;
- Updated pharmacovigilance obligations;
- Risk-management labeling;
- Hospital-use restrictions;
- Potential product-liability claims based on historical toxicity.
A new delivery system, such as a controlled-use applicator or low-exposure formulation, could create narrow patent opportunities. It would not eliminate the need for regulatory evidence supporting the reformulated product.
What is the likely generic launch scenario?
The most probable scenario is no major generic launch. If a manufacturer entered, the product would likely be distributed through institutional or specialty channels with a restricted label.
A commercially realistic launch would require:
- Confirmation that a viable U.S. regulatory pathway remains available.
- A differentiated clinical use that alternatives do not adequately address.
- Modern dermal-safety evidence.
- Contract manufacturing with validated topical capabilities.
- Institutional purchasing agreements before launch.
- Liability controls and restrictive distribution.
A broad retail relaunch is unlikely because of historical safety concerns, limited consumer demand, and strong competition from better-established antiseptics.
Key Takeaways
- PHISOHEX is a legacy hexachlorophene 3% topical antiseptic.
- No active clinical-trial or modern development program is identifiable.
- Hexachlorophene’s FDA history is defined by restrictions related to neonatal and pediatric neurotoxicity.
- No meaningful unexpired patent estate protects the historical product.
- Biosimilar competition is irrelevant because PHISOHEX is not a biologic.
- Generic legal entry risk is high, but commercial entry is unattractive.
- Chlorhexidine, povidone-iodine, and alcohol-based antiseptics are the principal alternatives.
- The market outlook is negligible to declining, with no credible basis for material revenue growth.
- Any relaunch would depend on regulatory, toxicology, manufacturing, and liability solutions rather than patent exclusivity.
FAQs About PHISOHEX
Is PHISOHEX still sold in the United States?
PHISOHEX does not have a meaningful current U.S. retail presence. Availability depends on the status of individual products, manufacturers, and distributors.
Can PHISOHEX be used on newborns?
Hexachlorophene products have significant restrictions for newborns and premature infants because of the risk of systemic absorption and neurotoxicity. Routine infant bathing is not an appropriate use.[1]
Is hexachlorophene stronger than chlorhexidine?
Hexachlorophene has persistent activity against selected gram-positive bacteria, but chlorhexidine has broader modern hospital use and stronger commercial support. Direct superiority depends on the organism, formulation, application, and clinical setting.
Does PHISOHEX have an FDA-approved generic?
A current, commercially significant FDA-approved generic market for PHISOHEX is not evident. Historical regulatory status and present product availability should be assessed separately.
Could a new PHISOHEX formulation receive patent protection?
A new formulation, applicator, or delivery system could potentially receive narrow patent protection if it meets novelty and non-obviousness requirements. Such protection would not cover hexachlorophene generally and would not remove the product’s safety and market-access challenges.
References
-
U.S. Food and Drug Administration. (n.d.). Hexachlorophene drug products: Labeling and safety information. FDA.
-
U.S. Food and Drug Administration. (1972). Hexachlorophene-containing preparations: Regulatory restrictions and safety communications. FDA.
-
National Library of Medicine. (n.d.). Hexachlorophene. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Hexachlorophene
